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Summary Tamoxifen has been implicated as a risk factor for venous thrombosis in advanced breast cancer
although the evidence for increased arterial or venous thrombosis with tamoxifen in early breast cancer is less
clear. The effect of tamoxifen on haemostasis, and thereby possible thromboembolic risk, was investigated in
normal women enrolled in a placebo controlled trial of tamoxifen as a chemopreventative agent for breast
cancer. There was an initial reduction in fibrinogen levels in all women on tamoxifen over the first year of
follow-up and a marginal reduction in antithrombin III and Protein S in postmenopausal women at 6 months.
There were no changes in cross linked fibrinogen degradation products or Protein C for pre or post-
menopausal women. There was no increase in the incidence of thromboembolic events on tamoxifen. This
study demonstrates that tamoxifen has only marginal effects on factors involved in haemostasis reported to
affect the incidence of arterial or venous thromboembolic disease. The follow-up time is relatively short
(maximum 36 months) and careful long term follow-up is necessary to detect clinically significant mor-
bidity.
Tamoxifen is widely used as adjuvant therapy in early breast
cancer and overview analysis of randomised tamoxifen trials
has demonstrated a prolongation of the disease-free interval
and an overall survival advantage for patients receiving
tamoxifen (EBCTCG, 1992; MacDonald et al., 1991).
Although tamoxifen is well tolerated with a low level of acute
side effects, the optimum duration of treatment is unclear
and there has only been limited data on long term side-effects
(Powles et al., 1989; 1990). Tamoxifen has both oestrogen
agonist and antagonist properties which are organ and
species specific, however, concern has been raised about
oestrogen antagonist activity and long term adverse effects,
for example on coagulation, lipid profile and cardiovascular
pathology (Fox et al., 1981). A number of anecdotal reports
have suggested that tamoxifen therapy is associated with an
increased risk of thromboembolic events in patients with
advanced breast cancer (Lipton et al., 1984; Nevasaari et al.,
1978; Hendrick & Subramanian 1980; Dahan et al., 1985),
however it is difficult to evaluate the contribution of tamox-
ifen to thrombosis in these patients because of the generally
increased risk of thrombosis in cancer patients per se. For
patients receiving tamoxifen as adjuvant therapy, the position
is even less clear. The frequency of arterial or venous throm-
bosis has been reported to be 5.4% among patients who
received adjuvant therapy compared with 1.6% in patients on
observation in a retrospective review of 2,673 patients (Saph-
ner et al., 1991). The risk ofthrombosis was highest for those
patients receiving tamoxifen together with chemotherapy
(Saphner et al., 1991) but tamoxifen as monotherapy was
only associated with a marginal, if any, increase in throm-
boembolic events (Saphner et al., 1991; Fornander et al.,
1991) and indeed it has been suggested that adjuvant tamox-
ifen may have a beneficial effect on thrombosis with a reduc-
tion in cardiovascular deaths (EBCTCG, 1992; MacDonald
et al., 1991).
We have investigated the effects of tamoxifen on coagula-
tion parameters in normal healthy women who had been
entered into a double-blind placebo controlled trial of tamox-
ifen as a chemopreventative agent in breast cancer (Powles et
al., 1989; 1990). Fibrinogen, a major predictor of cardiovas-
cular risk factor and cross linked fibrin degradation products
to detect increases in fibrinolysis were measured (EBCTCG,
1992; MacDonald et al., 1991). Antithrombin III, which
inhibits thrombin and other activated clotting factors, and
Protein C and Protein S which are important natural
inhibitors of coagulation (Esmon, 1987) were also assayed as
deficiencies of these factors may lead to a hypercoaguable
state and increased risk of thromboembolic events.
Patients, materials and methods
Normal healthy pre and postmenopausal women with a
positive maternal history of breast cancer were enrolled in a
double-blind placebo controlled pilot trial investigating the
use of tamoxifen as a chemopreventative agent in breast
cancer. The details of this trial haved been described
previously (Powles et al., 1989; 1990). Patients with a history
of venous thrombosis or pulmonary embolism were excluded.
Patients were prescribed 'tamoplac' and randomised in a
double-blind fashion to receive tamoxifen 20mg/day or a
placebo of identical appearance. A total of 515 patients had
pretreatment blood samples taken for fibrinogen and anti-
thrombin III assays and samples were repeated on treatment
at 6 monthly intervals. A subset of 39 consecutive patients
had pretreatment and on-treatment samples at 6 months for
Protein C, Protein S and cross linked fibrin degradation
products (XL-FDP).
Assays
Antithrombin III and Fibrinogen
Antithrombin III (AT3) and plasma fibrinogen were assayed
using functional photometric assays with the Cobus Mira
and kits supplied by Boehringer Mannheim (Kit 759 376 for
AT3 and Kit 524484 for fibrinogen). The methodology and
principle for the AT3 assay is described by Becker et al.
(Becker et al., 1984) and for fibrinogen by Hesse et al. (1981).
The normal range for AT3 was 20-291 U ml-' and for
fibrinogen 140-450 mg dl-'.
Protein C and Protein S
Protein C and Protein S antigen (bound and free) were
measured by enzyme linked immunosorbent assay) using
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peroxidase-conjugated rabbit anti-human Protein C and anti-
human Protein S polyclonal antibodies. (Dako Ltd, High
Wycombe, Buckinghamshire) (Avameas & Ternycke, 1971;
Woodhams, 1988).
The normal range for Protein C was 70-130 IU dl-' and
for Protein S normal range was 70-130% pooled normal
plasma.
Crosslinkedfibrin degradation products (XL-FDP)
XL-FDP were measured by an immunoassay (Dimertest
Enzyme Immunoassay supplied by Porton Cambridge Ltd,
Maidenhead, Berkshire). The method employs a monoclonal
antibody which recognises D-dimer and fragments containing
the D-dimer epitope (Rylatt et al., 1988) (normal range
<250 ng ml-').
Statistics
Results have been analysed for each treatment group as a
whole and separately for pre and postmenopausal women
and expressed as a percentage of the pretreatment value
(± s.e.m.) for each group. The t-test was used to assess the
significance of the change from the pretreatment value at
each 6 monthly time point.
Results
For premenopausal women there was a reduction in plasma
fibrinogen levels at 6 months on tamoxifen to 90% (± 7%)
of pretreatment values (P<0.005) and this fall was sustained
over the first year of follow-up (P<0.001) (Figure la). This
represents a mean fall in fibrinogen of 28 mgdl-'. For post-
menopausal women there was a similar reduction to 85%
(± 5%) of pretreatment values (P<0.001) sustained over the
first year (P<0.02) representing a mean fall of 46mgdl-'
(Figure lb). After 12 months there was no apparent
difference in fibrinogen levels but numbers ofpatients at each
time point are low.
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There was no reduction in antithrombin 3 on treatment for
premenopausal women (Figure 2b), however there was a
reduction in antithrombin 3 for postmenopausal women
(Figure 2a) to 96% ± 3% of pretreatment values at 12
months (P<0.05).
For premenopausal women there was no change in Protein
S antigen or Protein C on treatment (Figure 3). For post-
menopausal women there was an overall marginal reduction
in Protein antigen to 90% of pretreatment levels at 6 months
(P = 0.05) but no change in Protein C levels (Figure 4). No
subject had pretreatment. values of Protein C or Protein S
antigen below 50% of the normal range. There were no
significant changes in crosslinked FDP's for either pre or
postmenopausal women on treatment with no value outside
the normal range (250 mgml-').
No thromboembolic events have been recorded so far in
either arm.
Discussion
Tamoxifen has been implicated as a risk factor for throm-
boembolic disease however the only evidence for this has
come from reports of patients with advanced disease in
whom the presence of a hypercoaguable state may be mul-
tifactorial. This study has allowed evaluation of tamoxifen on
coagulation factors in a placebo controlled trial in a popula-
tion of normal women. Although the reduction in fibrinogen
was no longer apparent after 12 months, this may be a
reflection of low patient numbers at the later time points.
Fibrinogen, the plasma precursor of fibrin, is recognised as
an important factor in the pathogenesis of arterial throm-
botic disease and increased plasma levels are a major risk
factor for ischaemic heart disease independent of the in-
creased risk associated with high plasma cholesterol concen-
tration (Becker et al., 1984; Lowe et al., 1991). In this study
in normal women there was no increase in fibrinogen levels
and indeed for both pre and postmenopausal women on
tamoxifen there was a significant reduction in fibrinogen
levels. This reduction was sustained over the first year of
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Figure 1 Change in fibrinogen on tamoplac expressed as a
percentage of pretreatment values for a, premenopausal patients;
b, postmenopausal patients. ---- = Tamoxifen, -- =
placebo.
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Figure 2 Antithrombin III levels on tamoplac expressed as a
percentage ofpretreatment values for a, postmenopausal patients:
b, premenopausal patients. 0*-- = Tamoxifen, *-- =
placebo.
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Figure 3 Protein C levels at 6 months expressed
of pretreatment values.
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Figure 4 Protein S antigen levels
percentage of pretreatment values.
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In our study there was no reduction in Protein C at 6 months
and there was only a marginal reduction in Protein S in
postmenopausal patients. Although congenital Protein S
deficiency is a risk factor for venous thrombosis and has also
been implicated as a risk factor for arterial thrombosis
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antithrombin III levels on tamoxifen suggests that the pattern
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patients on long-term adjuvant tamoxifen are also stable with
time (Langan-Fahey, 1991).
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